āĻšā§āĻŽNVO âĸ NYSE
add
Novo Nordisk A/S
ā§Šā§.ā§Ēā§Ģ$
āĻāĻŖā§āĻāĻž āĻĒāϰā§:(ā§Ļ.ā§§ā§§%)+ā§Ļ.ā§Ļā§Šā§¯
ā§Šā§.ā§Ē⧝$
āĻŦāύā§āϧ āĻāĻā§: ⧍⧠āĻĢā§āĻŦ, ā§:ā§Ģ⧝:ā§§ā§Ģ PM GMT -ā§Ģ · USD · NYSE · āĻĄāĻŋāϏāĻā§āϞā§āĻŽāĻžāϰ
āϏā§āĻāĻāĻŽāĻžāϰā§āĻāĻŋāύ āϝā§āĻā§āϤāϰāĻžāώā§āĻā§āϰ-āĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āϏāĻŋāĻāĻŋāĻāϰāĻŋāĻāĻŋDK-āĻ āĻšā§āĻĄāĻā§ā§āĻžāϰā§āĻāĻžāϰ
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§Šā§.ā§Ŧ⧍$
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
ā§Šā§.ā§Šā§Š$ - ā§Šā§.ā§Žā§Ŧ$
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
ā§Šā§.ā§Šā§§$ - ⧝⧧.⧝ā§Ļ$
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§§.⧍ā§āĻā§ USD
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
⧍.ā§Žā§Ē āĻā§
P/E āĻ
āύā§āĻĒāĻžāϤ
ā§§ā§Ļ.ā§Šā§Ļ
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
ā§Ē.⧝ā§%
āĻāĻŦāϰ⧠āϰā§ā§āĻā§
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
| (DKK) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§.⧝⧧āĻļāĻ¤Â āĻā§ | -ā§.ā§Ŧā§Š% |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ⧍.⧝ā§āĻļāĻ¤Â āĻā§ | ⧧⧍.⧝ā§Ŧ% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | ⧍.ā§Ŧ⧝āĻļāĻ¤Â āĻā§ | -ā§Ē.ā§ā§Ē% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | ā§Šā§Š.ā§¯ā§Ž | ā§Š.ā§§ā§Š% |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | ā§Ŧ.ā§Ļā§Ē | -ā§Ē.ā§ā§Š% |
EBITDA | ā§Š.ā§Ŧā§āĻļāĻ¤Â āĻā§ | -ā§¨ā§Š.ā§Ēā§Ē% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | ⧍⧧.ā§Šā§Ē% | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (DKK) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ⧍.ā§ā§ĻāĻļāĻ¤Â āĻā§ | ⧍.ā§Ē⧝% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§Ģ.ā§Ēā§ŠāĻā§ | ā§§ā§Ŧ.ā§Ŧā§Ļ% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§Š.ā§Ē⧝āĻā§ | ā§Ž.⧍⧝% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§§.⧝ā§ĒāĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§Ēā§Ēā§Ē.ā§Ēā§Ļ āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§Ļ.ā§Žā§Ŧ | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§§ā§Ŧ.ā§ā§Ļ% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | ⧍⧝.ā§Ģā§Ŧ% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
| (DKK) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | ⧍.ā§Ŧ⧝āĻļāĻ¤Â āĻā§ | -ā§Ē.ā§ā§Ē% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | ā§ā§Ŧā§§.⧝ā§Ļ āĻā§ | -ā§Šā§Ž.ā§Ļā§Ŧ% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -ā§Ē.ā§¨ā§ŽāĻļāĻ¤Â āĻā§ | ā§Ģā§Š.ā§Ļā§% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ⧍.⧝ā§ĢāĻļāĻ¤Â āĻā§ | -⧍ā§Ļ.ā§Ļā§Ļ% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | -ā§Ģā§Ŧ⧍.ā§Ļā§Ļ āĻā§ | ā§Žā§Ŧ.ā§Ēā§§% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| -ā§Š.ā§Ē⧝āĻļāĻ¤Â āĻā§ | -ā§§,ā§Ļā§§ā§§.ā§Ļ⧝% |
āϏāĻŽā§āĻĒāϰā§āĻā§
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in BagsvÃĻrd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
⧍⧧ āĻĄāĻŋāϏā§, ā§§ā§¯ā§¨ā§Š
āϏāĻĻāϰ āĻĻāĻĒā§āϤāϰ
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
ā§Ŧ⧝,ā§§ā§Ģā§Ļ